Clinical trial

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results

Thursday, October 29, 2020 - 8:00pm

Present updated clinical data from the CPI-818 Phase 1/1b clinical trial at the American Society of Hematology (ASH) annual meeting in December 2020.

Key Points: 
  • Present updated clinical data from the CPI-818 Phase 1/1b clinical trial at the American Society of Hematology (ASH) annual meeting in December 2020.
  • Research and development expenses for the three months ended September 30, 2020 totaled $6.6 million compared to $9.0 million for the same period in 2019.
  • General and administrative expenses for the three months ended September 30, 2020 totaled $3.2 million dollars compared to $2.5 million for the same period in 2019.
  • The Company was launched through a collaboration with U.S.-based Corvus Pharmaceuticals and investments from investors in China.

HOOKIPA Announces First Patient Dosed in Phase 1/2 Clinical Trial for HB-202/HB-201 Alternating Vector Therapy to Treat Human Papillomavirus 16-Positive Cancers

Thursday, October 29, 2020 - 11:30am

HB-202 is part of a sequential alternating regimen of HB-202/HB-201 for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in the ongoing HB-201 Phase 1/2 trial (NCT04180215).

Key Points: 
  • HB-202 is part of a sequential alternating regimen of HB-202/HB-201 for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in the ongoing HB-201 Phase 1/2 trial (NCT04180215).
  • The alternating, sequential HB-202/HB-201 two-vector therapy has been incorporated into the ongoing Phase 1/2 trial (NCT04180215).
  • This Phase 1/2 clinical trial is an open-label dose-escalation and dose-expansion trial in patients with treatment-refractory HPV16+ cancers.
  • HOOKIPAs non-replicating prophylactic Cytomegalovirus (CMV) vaccine candidate is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation.

Seqster Partners with Takeda to Help Digitally Transform Patient Experiences

Thursday, October 29, 2020 - 11:00am

Seqster's technology supports real-time, real-world data and targeted patient engagement, which includes FDA 21 CFR Part 11 compliance.

Key Points: 
  • Seqster's technology supports real-time, real-world data and targeted patient engagement, which includes FDA 21 CFR Part 11 compliance.
  • Seqster's decision support system and research platform dramatically reduces the time for consenting and onboarding patient data during clinical trials.
  • This enhances patient engagement and compliance through a single-entry point for EHRs and integrates with partners enterprise data backbones.
  • Our technology will help Takeda accelerate transforming clinical development in the post-COVID era, improving patient engagement and services, and streamlining safety and efficacy demonstration.

Plus Therapeutics Announces Initiation of Final Cohort of ReSPECT™ Glioblastoma Trial

Thursday, October 29, 2020 - 11:00am

Initiation of the sixth dose cohort follows successful completion of the fifth cohort and clearance from the ReSPECT trials Data and Safety Monitoring Board (DSMB).

Key Points: 
  • Initiation of the sixth dose cohort follows successful completion of the fifth cohort and clearance from the ReSPECT trials Data and Safety Monitoring Board (DSMB).
  • The sixth cohort of the ReSPECT trial includes an increase in both the RNL drug volume and radiation dose to 8.8 milliliters and 22.3 millicuries, respectively.
  • Cohort progression in our ReSPECT trial represents another milestone toward the trials first major readout, said Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics.
  • Plus Therapeutics will be presenting data from the ReSPECT clinical trial at the 2020 Society for Neuro-Oncology (SNO) Annual Meeting being held virtually November 19-21, 2020.

Aerie Pharmaceuticals Initiates Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patients with Dry Eye Disease

Thursday, October 29, 2020 - 10:30am

The COMET-1 trial is a randomized, double-masked, vehicle-controlled trial evaluating the efficacy and safety of AR-15512 (TRPM8 agonist) in patients with dry eye disease.

Key Points: 
  • The COMET-1 trial is a randomized, double-masked, vehicle-controlled trial evaluating the efficacy and safety of AR-15512 (TRPM8 agonist) in patients with dry eye disease.
  • The primary efficacy endpoints of the clinical trial are ocular discomfort (symptom) and tear production (sign).
  • Patients will be evaluated on multiple efficacy assessments at days 14, 28 and 84; safety will be assessed at all visits.
  • We are excited to initiate COMET-1, Aeries first dry eye clinical trial, said Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer at Aerie.

L'Oréal signs license agreement with Dutch biotech Micreos, world leader in targeted bacterial biotechnology

Thursday, October 29, 2020 - 8:15am

Under the terms of the agreement, Micreos will give L'Oral access to its endolysin, a type of active protein in the cosmetic field.

Key Points: 
  • Under the terms of the agreement, Micreos will give L'Oral access to its endolysin, a type of active protein in the cosmetic field.
  • For 15 years, L'Oral's Research & Innovation has been cooperating with scientific institutions and conducting clinical studies to better understand the role of the skin microbiome.
  • "The agreement with Micreos opens up a very promising field in high-tech cosmetics," says Laurent Attal, Executive Vice-President Research & Innovation of L'Oral.
  • Micreos is at the forefront of targeted bacterial biotechnology.

L'Oréal signs license agreement with Dutch biotech Micreos, world leader in targeted bacterial biotechnology

Thursday, October 29, 2020 - 8:15am

Under the terms of the agreement, Micreos will give L'Oral access to its endolysin, a type of active protein in the cosmetic field.

Key Points: 
  • Under the terms of the agreement, Micreos will give L'Oral access to its endolysin, a type of active protein in the cosmetic field.
  • For 15 years, L'Oral's Research & Innovation has been cooperating with scientific institutions and conducting clinical studies to better understand the role of the skin microbiome.
  • "The agreement with Micreos opens up a very promising field in high-tech cosmetics," says Laurent Attal, Executive Vice-President Research & Innovation of L'Oral.
  • Micreos is at the forefront of targeted bacterial biotechnology.

DGAP-News: CytoTools starts phase III study of DermaPro in Europe

Thursday, October 29, 2020 - 9:01am

Darmstadt, 29 October 2020 - The Management Board of CytoTools AG (ISIN DE000A0KFRJ1), a biotechnology holding company specializing in pharmaceutical and medical products, has started the phase III clinical study for the approval of its wound healing product DermaPro in Europe as announced.

Key Points: 
  • Darmstadt, 29 October 2020 - The Management Board of CytoTools AG (ISIN DE000A0KFRJ1), a biotechnology holding company specializing in pharmaceutical and medical products, has started the phase III clinical study for the approval of its wound healing product DermaPro in Europe as announced.
  • Recruitment will initially start in Germany and will be extended to up to seven other countries in the coming months.
  • "This was over 76 percent in all groups of test persons in the Indian phase III study.
  • According to the current milestone planning of the European Phase III study, the Company expects the study to be completed in the fourth quarter of 2022.

Geron Announces Publication of IMerge Phase 2 Data in Journal of Clinical Oncology

Wednesday, October 28, 2020 - 8:35pm

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that data from the IMerge Phase 2 trial were published in the Journal of Clinical Oncology.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that data from the IMerge Phase 2 trial were published in the Journal of Clinical Oncology.
  • The publication reports efficacy, safety and biomarker results from the IMerge Phase 2 clinical trial.
  • We are pleased that the IMerge Phase 2 data have been published in one of the most prestigious oncology journals, the Journal of Clinical Oncology, and we believe that the publication of these data in JCO represents an increased level of interest from the oncology community, said Aleksandra Rizo, M.D., Ph.D., Gerons Chief Medical Officer.
  • The IMerge Phase 2 is no longer enrolling patients and patients remaining in the treatment phase continue to receive imetelstat treatment, per investigator discretion.

Global Clinical Trials Market 2020-2025 - Leveraging Online Resources to Increase Patient Recruitment Rates in Clinical Trials - ResearchAndMarkets.com

Wednesday, October 28, 2020 - 4:52pm

The "Global Clinical Trials Market 2020-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Clinical Trials Market 2020-2025" report has been added to ResearchAndMarkets.com's offering.
  • With the increase in the demand for new medicines and medical equipment amongst the healthcare providers, the clinical trials markets has seen an upsurge.
  • However, solutions that are both permanent and effective do take a considerable amount of time in terms of approval thus slowing down the market growth.
  • Clinical trials are scientific studies to understand how a particular medical approach reciprocates in different sets of people.